Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Analyst Ratings for Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Truist Securities Maintains Buy on Axonics, Lowers Price Target to $82
Truist Securities analyst David Rescott maintains Axonics (NASDAQ:AXNX) with a Buy and lowers the price target from $90 to $82.
Jefferies Initiates Coverage On Axonics with Hold Rating, Announces Price Target of $75
Jefferies analyst Matthew Taylor initiates coverage on Axonics (NASDAQ:AXNX) with a Hold rating and announces Price Target of $75.
Morgan Stanley Maintains Overweight on Axonics, Raises Price Target to $92
Morgan Stanley analyst Cecilia Furlong maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $80 to $92.
Piper Sandler Maintains Overweight on Axonics, Raises Price Target to $84
Piper Sandler analyst Adam Maeder maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $82 to $84.
Axonics Announced First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (Nasdaq: AXNX) today announced the first patient implants in Canada with the Axonics F15™, the company's newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
Axonics Expands Sacral Neuromodulation Intellectual Property Portfolio
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months,